mash semaglutide in with F2-F3 fibrosis: a holistic perspective on the ESSENCE phase 3 trial CDSCO Approves Wegovy for MASH

No dose adjustment is required for patients with kidney impairment

Hypothalamic Appetite Signaling: Analyzing central nervous system interaction, specifically how the peptide accesses and stimulates pro-opiomelanocortin (POMC) neurons to regulate satiety signaling

The end of that shortage has implications for the ongoing regulatory environment around compounded semaglutide, and patients should stay informed about how evolving FDA guidance may affect compounded product availability

How It Helps: By engaging dual pathways, Tirzepatide offers robust support for appetite control, insulin sensitivity, and metabolic rate regulation

Congratulations to Mette Klausen, Anders Fink-Jensen and the rest of the illustrious team